Trial reportHerz2015
Role of cathepsin D activation in major adverse cardiovascular events and new-onset heart failure after STEMI.
Trial report in Herz, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Circulating protein biomarkers and their association with vulnerable plaque characteristics - a PROSPECT II substudy.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Cathepsin-D and outcomes in peripartum cardiomyopathy: Results from IPAC.American heart journal plus : cardiology research and practice · 2025Article
- Genetic insights into the role of cathepsins in cardiovascular diseases: a Mendelian randomization study.ESC heart failure · 2024Article
- Emerging Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease.Life (Basel, Switzerland) · 2023Review
- Cathepsin D-Managing the Delicate Balance.Pharmaceutics · 2021Review
- Biomarker Discovery of Acute Coronary Syndrome Using Proteomic Approach.Molecules (Basel, Switzerland) · 2021Article
- Identification of monocyte-associated genes as predictive biomarkers of heart failure after acute myocardial infarction.BMC medical genomics · 2021Article
- Platelet proteome changes in dogs with congestive heart failure.BMC veterinary research · 2020Article
- The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach.European journal of heart failure · 2020Article
- Article
- Myocardial Upregulation of Cathepsin D by Ischemic Heart Disease Promotes Autophagic Flux and Protects Against Cardiac Remodeling and Heart Failure.Circulation. Heart failure · 2017Article
- Admission Value of Serum Cathepsin D Level Can be Useful for Predicting In-Hospital Mortality in Patients with NSTEMI.Acta Cardiologica Sinica · 2017Article
- Increased Cathepsin D Correlates with Clinical Parameters in Newly Diagnosed Type 2 Diabetes.Disease markers · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIncreased serum levels of the activated aspartic lysosomal endopeptidase cathepsin D (CatD) have been found in patients with acute myocardial infarction (AMI). However, to date there have been no analyses of clinical follow-up data measuring the enzyme course and its role in the development of post-MI heart failure. This study aimed to evaluate the role of serum CatD activity in the development of heart failure in patients with ST-segment elevation acute myocardial infarction (STEMI). PATIENTS AND
methodsEighty-eight consecutive patients (79.5 % men, mean age 57.4 ± 10.2 years) with STEMI were included in this study. Serum CatD activity was measured directly after primary percutaneous coronary intervention (PCI), before discharge, and at the 6-month follow-up. Patients were monitored for major adverse cardiovascular events (MACE), defined as hospitalization due to cardiovascular causes, recurrent nonfatal myocardial infarction, unplanned PCI, new-onset heart failure, and cardiovascular mortality.
resultsSerum CatD activity was significantly higher in patients with AMI after PCI and during follow-up (FU) than that in age-matched controls (16.2 ± 7.5 and 29.8 ± 8.9 vs. 8.5 ± 4.2 RFU; p < 0.001 for each time point). At the 6-month follow-up, serum CatD activity in these patients was inversely related to new-onset cardiac dysfunction compared with patients with preserved and improved LVEF after treatment (23.1 ± 3.2 vs. 28.8 ± 7.0 and 29.7 ± 5.0 RFU respectively, p < 0.01). Patients suffering from MACE during a follow-up period of 6 months had lower serum levels of activated CatD than those without any MACE (23.8 ± 4.6 vs 29.6 ± 6.9 RFU; p < 0.001).
conclusionsSerum CatD activity as a marker of healthy endogenous phagocytosis and remodeling was impaired in patients with new-onset cardiac dysfunction, and lower levels of serum CatD were associated with MACE at the 6-month post-MI follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.